Hydroxy, Bonded Directly To Carbon, Or Ether Oxygen Attached Directly Or Indirectly To The Acyclic Carbon Or Chain By Acyclic Nonionic Bonding With No Amino Nitrogen Between The Hydroxy Or Ether Oxygen And The Aryl Ring Or Ring System (h Of -oh May Be Replaced By A Substituted Or Unsubstituted Ammonium Ion Or A Group Ia Or Iia Light Metal) Patents (Class 564/355)
  • Patent number: 9944618
    Abstract: This document relates to compounds as well as methods and materials involved in modulating neurotransmitter reuptake. For example, compounds, methods for synthesizing compounds, and methods for inhibiting neurotransmitter reuptake are provided. Specifically gamma-amino alcohol derivatives that inhibit the reuptake of neurotransmitters such as dopamine, serotonin, epinephrine or norepinephrine are provided as therapeutic agents for the treatment of depression or anxiety in a mammalian subject.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: April 17, 2018
    Assignees: Mayo Foundation for Medical Education and Research, Virginia Tech Intellectual Properties, Inc.
    Inventors: Elliott Richelson, Abdul H. Fauq, Paul Carlier, Christopher J. Monceaux
  • Publication number: 20150105559
    Abstract: Disclosed is a method for producing a compound having an amino group and/or a hydroxyl group from a substrate compound having an atomic group containing CO or CS by eliminating such atomic group. The substrate compound, having an atomic group containing CO or CS (for example, an amide, a carbamate, or the like), is allowed to react with a compound expressed by formula (I) below, at a temperature of 120° C. or lower, preferably in the presence of an ammonium salt, to eliminate such atomic group containing CO or CS. In formula (I) A may not be present, and in a case where A is present, A represents an alkyl group having 1 to 6 carbon atoms. H2N-A—NH2 (I) - - -.
    Type: Application
    Filed: March 4, 2013
    Publication date: April 16, 2015
    Applicant: Kyushu University, National University Corporation
    Inventors: Takashi Ohshima, Hiroyuki Morimoto, Yuhei Shimizu
  • Patent number: 8987262
    Abstract: The present technology relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present technology provides an alternative to the known compounds, e.g. corticosteroïds, interferon or vincristine, generally used for the treatment of hemangiomas.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: March 24, 2015
    Assignees: Universite de Bordeaux, Centre Hospitalier Universitaire de Bordeaux
    Inventors: Christine Leaute-Labreze, Eric Dumas De La Roque, Alain Taieb, Jean-Benoit Thambo
  • Publication number: 20150071969
    Abstract: Levalbuterol L-tartrate affords crystals possessing properties desirable for use in a metered dose inhaler.
    Type: Application
    Filed: May 21, 2014
    Publication date: March 12, 2015
    Applicant: SUNOVION PHARMACEUTICALS INC.
    Inventors: Paul MCGLYNN, Roger Bakale, Craig Sturge
  • Patent number: 8962865
    Abstract: A process is disclosed for the preparation of a compound of formula and/or an addition salt of a proton acid, wherein R1 and R2 independently represent alkyl, cycloalkyl, aryl or aralkyl, each aryl or aralkyl being optionally further substituted with alkyl, alkoxy and/or halogen.
    Type: Grant
    Filed: July 25, 2013
    Date of Patent: February 24, 2015
    Assignee: Lonza AG
    Inventors: Dominique Michel, Rudolf Fuchs
  • Publication number: 20150038705
    Abstract: Compounds, compositions, and methods comprising a polyamine compound are described, which may be used to kill, disperse, treat, reduce biofilms, and/or inhibit or substantially prevent biofilm formation. In certain aspects, the present invention relates to compounds, compositions, and methods comprising polyamine compounds that have antimicrobial or dispersing activity against a variety of bacterial strains capable of forming biofilms.
    Type: Application
    Filed: October 6, 2014
    Publication date: February 5, 2015
    Inventors: DUSTIN WILLIAMS, RYAN LOOPER, SUJEEVINI JEYAPALINA, TRAVIS HAUSSENER, PAUL R. SEBAHAR, HARI KANNA REDDY
  • Patent number: 8932980
    Abstract: The invention discloses three-dimensional, ordered, mesoporous titanosilicates wherein the Ti is in a tetrahedral geometry and exclusively substituted for Si in the silica framework. Such titanosilicates find use as catalysts for epoxidation, hydroxylation, C—H bond oxidation, oxidation of sulfides, aminolysis of epoxide and amoximation, with approx. 100% selectivity towards the products.
    Type: Grant
    Filed: July 20, 2011
    Date of Patent: January 13, 2015
    Assignee: Council of Scientific & Industrial Research
    Inventors: Srinivas Darbha, Anuj Kumar
  • Publication number: 20140357859
    Abstract: The invention concerns a new process for the resolution of ivabradine and of intermediates of synthesis thereof.
    Type: Application
    Filed: July 31, 2012
    Publication date: December 4, 2014
    Applicant: LOBORATORIO CHIMICO INTERNAZIONALE S.p.A.
    Inventors: Antonio Nardi, Bruno De Angelis, Paolangelo Cerea, Jane Llorenc Rafecas, Nicolas Tesson
  • Patent number: 8884062
    Abstract: This invention provides a compound of the formula (I): wherein the ring A is an optionally substituted carbocyclic group or an optionally substituted heterocyclic group; R1 is optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl; R2a and R2b are each independently hydrogen, optionally substituted lower alkyl or optionally substituted acyl; R3a, R3b, R3c and R3d are each independently hydrogen, halogen, hydroxy or optionally substituted lower alkyl etc.; a pharmaceutically acceptable salt or solvate thereof, which is useful for treating diseases induced by production, secretion and/or deposition of amyloid ? protein.
    Type: Grant
    Filed: May 6, 2013
    Date of Patent: November 11, 2014
    Assignee: Shionogi & Co., Ltd.
    Inventors: Yuusuke Tamura, Shinji Suzuki, Yukio Tada, Shuji Yonezawa, Chiaki Fujikoshi, Sae Matsumoto, Yuuji Kooriyama, Tatsuhiko Ueno
  • Patent number: 8877974
    Abstract: The present invention relates to a process for the preparation of (1R,2R)-3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol.
    Type: Grant
    Filed: July 23, 2007
    Date of Patent: November 4, 2014
    Assignee: Grünenthal GmbH
    Inventors: Wolfgang Hell, Oswald Zimmer, Helmut Heinrich Buschmann, Joerg Holenz, Stefan Gladow
  • Patent number: 8853452
    Abstract: Compounds and their syntheses are disclosed herein. Compositions and pharmaceutical compositions comprising a compound are also described, and include compositions also comprising liposomes. Methods for the treatment of cancer in animals comprising administering a compound or a composition comprising a compound are also described.
    Type: Grant
    Filed: February 9, 2010
    Date of Patent: October 7, 2014
    Assignee: The Administrators of the Tulane Educational Fund
    Inventors: Barbara S. Beckman, Maryam Foroozesh, Jiawang Liu
  • Patent number: 8809304
    Abstract: A novel amine compound represented by the following formula (I), which is superior in immunosuppressive action, rejection suppressive action and the like, and shows reduced side effects such as bradycardia and the like, or a pharmaceutically acceptable acid addition salt thereof, or hydrates thereof, or solvate, as well as a pharmaceutical composition containing this compound and a pharmaceutically acceptable carrier. wherein R is a hydrogen atom or P(?O)(OH)2, X is an oxygen atom or a sulfur atom, Y is CH2CH2 or CH?CH, R1 is cyano or alkyl having a carbon number of 1 to 4 and substituted by a halogen atom(s), R2 is alkyl having a carbon number of 1 to 4 and optionally substituted by a hydroxyl group(s) or a halogen atom(s), R3 and R4 may be the same or different and each is a hydrogen atom or alkyl having a carbon number of 1 to 4, and n is 5-8.
    Type: Grant
    Filed: December 15, 2006
    Date of Patent: August 19, 2014
    Assignee: Mitsubishi Tanabe Pharma Corporation
    Inventors: Masatoshi Kiuchi, Kaoru Marukawa, Nobutaka Kobayashi, Kunio Sugahara
  • Publication number: 20140228443
    Abstract: Provided are compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions.
    Type: Application
    Filed: February 7, 2014
    Publication date: August 14, 2014
    Applicant: Acucela Inc.
    Inventors: Ian L. Scott, Vladimir A. Kuksa, Feng Hong, Ryo Kubota, Jennifer Gage
  • Publication number: 20140228380
    Abstract: The present invention provides a method of inhibiting, suppressing or preventing levodopa-induced dyskinesia in a patient suffering from Parkinson's Disease, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention. The present invention further provides a method of inhibiting, suppressing or preventing Parkinson's Disease in a patient, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention.
    Type: Application
    Filed: August 2, 2013
    Publication date: August 14, 2014
    Applicants: University of Medicine and Dentistry New Jersey Medical School, Philadelphia Health & Education Corporation d/b/a Drexel University College of Medicine
    Inventors: Sandhya Kortagere, Eldo V. Kuzhikandahil
  • Publication number: 20140128614
    Abstract: To provide pesticidal allylAryl heterocycle derivatives that are useful as a pesticidal compound. Pesticidal allylAryl heterocycle derivatives that are expressed by the Formula (I), and pesticides and an agent for controlling animal parasites which include the allylAryl heterocycle derivatives as an effective component.
    Type: Application
    Filed: April 24, 2012
    Publication date: May 8, 2014
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Mamoru Hatazawa, Tetsuya Murata, Peter Bruechner, Daiei Yamazaki, Eiichi Shimojo, Teruyuki Ichihara, Katsuhiko Shibuya, Tadashi Ishikawa
  • Patent number: 8674137
    Abstract: Provided are compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions.
    Type: Grant
    Filed: October 21, 2009
    Date of Patent: March 18, 2014
    Assignee: Acucela Inc.
    Inventors: Ian L. Scott, Vladimir Aleksandrovich Kuksa, Feng Hong, Ryo Kubota, Jennifer Gage
  • Patent number: 8618326
    Abstract: Disclosed is a method of making a 2-substituted-1,4-benzenediamine by nucleophilic aromatic substitution.
    Type: Grant
    Filed: January 28, 2011
    Date of Patent: December 31, 2013
    Assignee: The Procter & Gamble Company
    Inventors: John Michael Gardlik, Garry Steven Garrett, Bryan Patrick Murphy, Guiru Zhang, Robert Edward Shumate, James S. Anderson
  • Publication number: 20130296608
    Abstract: The present invention relates to a novel stereospecific synthesis of (?)(2S,3S)-1-dimethylamino-3-(3-methoxyphenyl)-2-methyl pentan-3-ol an intermediate in the synthesis of 3-[(1R,2R)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol.
    Type: Application
    Filed: January 27, 2011
    Publication date: November 7, 2013
    Applicant: SYMED LABS LIMITED
    Inventors: Dodda Mohan Rao, Pingili Krishnareddy, Pingili Ramachandrareddy, Kirla Haritha, Kolluru Srinivas
  • Publication number: 20130274280
    Abstract: This invention provides an oral pharmaceutical composition comprising a physiologically tolerable gelled oil-in-water emulsion containing a drug of abuse.
    Type: Application
    Filed: April 11, 2011
    Publication date: October 17, 2013
    Applicant: AYANDA GROUP AS
    Inventors: Kurt Ingar Draget, Ingvild Johanne Haug, Steinar Johan Engelsen, Tore Seternes, Magnus N. Hattrem
  • Patent number: 8524951
    Abstract: Disclosed is a process for producing 1-hydroxy-4-aminoadamantane.
    Type: Grant
    Filed: July 15, 2011
    Date of Patent: September 3, 2013
    Assignee: Shionogi & Co., Ltd.
    Inventor: Hideaki Watanabe
  • Publication number: 20130210835
    Abstract: A composition of an antitussive, a decongestant, or an antihistamine to treat respiratory and oral pharyngeal congestion and related symptoms in a patient.
    Type: Application
    Filed: June 13, 2011
    Publication date: August 15, 2013
    Applicant: GM PHARMACEUTICAL, INC
    Inventor: Odes W. Mitchell
  • Publication number: 20130197096
    Abstract: The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are alkoxyl derivative compounds and pharmaceutical compositions comprising these compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.
    Type: Application
    Filed: September 14, 2012
    Publication date: August 1, 2013
    Applicant: Acucela, Inc.
    Inventors: Ian L. Scott, Vladimir A. Kuksa, Mark W. Orme, Thomas Little, Anna Gall, Feng Hong
  • Patent number: 8476305
    Abstract: A novel therapeutic agent or prophylactic agent for an inflammatory bowel disease is provided. An amino alcohol derivative represented by the general formula (1): which is a sphingosine-1-phosphate receptor agonist or a pharmaceutically acceptable salt or hydrate thereof are a therapeutic agent or prophylactic agent for an inflammatory bowel disease comprises.
    Type: Grant
    Filed: February 6, 2009
    Date of Patent: July 2, 2013
    Assignee: Kyorin Pharmaceutical Co., Ltd.
    Inventors: Naoya Yamamuro, Koichi Nakamaru, Tokutarou Yasue
  • Publication number: 20130165648
    Abstract: The present invention provides processes and intermediates for the preparation of 3-benzazepines and salts thereof which can be useful as serotonin (5-HT) receptor agonists for the treatment of, for example, central nervous system disorders such as obesity.
    Type: Application
    Filed: September 14, 2012
    Publication date: June 27, 2013
    Inventors: Beverly L. Wolgast, Charles A. Gilson, III, Shelley Aytes, Scott A. Estrada, Dipanjan Sengupta, Brian Smith, Max Rey, Ulrich Weigl, Heidedore Jlsabeth Rey-Papina
  • Patent number: 8455692
    Abstract: Resolution of the title compound to its active isomer (R)-1-(3-hydroxyphenyl)-2-methylamino ethanol with (R)-naproxen as a resolving agent.
    Type: Grant
    Filed: December 22, 2010
    Date of Patent: June 4, 2013
    Assignee: Divi's Laboratories, Ltd.
    Inventors: Murali Krishna Prasad Divi, Padakandla Gundu Rao, Bolneni Nageswara Rao, Medepudi Ramesh Babu, Mutyala Krishnaji Rao, Allupati Padmanav Patro
  • Publication number: 20130137890
    Abstract: Disclosed herein is an improved process for the preparation of 3-[(2R,3R)-1-(dimethylamino)-2-methylpentan-3-yl]phenol of Formula-I and its pharmaceutically acceptable salt which comprises the reaction of (S)-1-(dimethylamino)-2-methylpentan-3-one of formula VIII with 3-bromo anisole of formula II under Grignard conditions to get the compound (2S, 3R)-1-(dimethylamino)-3-(3-methoxyphenyl)-2-methyl pentan-3-ol of formula V followed by activation of the —OH group of the formula V to convert into sulfonate esters of formula IX, which are on reductive deoxygenation to yield (2R,3R)-3-(3-methoxyphenyl)-N,N,2-trimethylpentan-1-amine of formula VII and demethylation of formula VII to obtain the compound 3-[(2R,3R)-1-(dimethylamino)-2-methylpentan-3-yl]phenol of Formula-1.
    Type: Application
    Filed: August 16, 2011
    Publication date: May 30, 2013
    Applicant: Indoco Remedies Limited
    Inventors: Mangesh Narayan Rajadhyaksha, Ranjeet Nair, Sandip Kacharu Deshmukh, Somnath Ambadas Khabale, Aditi Milind Panandikar
  • Publication number: 20130123539
    Abstract: Methods for preparing Ritodrine hydrochloride are provided. Also provided is non-hygroscopic, crystalline, polymorphic Ritodrine hydrochloride of Form I.
    Type: Application
    Filed: March 24, 2011
    Publication date: May 16, 2013
    Inventor: Jacopo Zanon
  • Patent number: 8440863
    Abstract: The present invention relates to an improved process for the preparation of (2R,3R)-3-(3-methoxyphenyl)-N,N,2-trimethylpentanamine which is an intermediate for the preparation of the analgesic tapentadol.
    Type: Grant
    Filed: February 15, 2012
    Date of Patent: May 14, 2013
    Assignee: Janssen Pharmaceutica, NV
    Inventors: Walter Ferdinand Maria Filliers, Rudy Laurent Maria Broeckx
  • Publication number: 20130116453
    Abstract: The invention discloses three-dimensional, ordered, mesoporous titanosilicates wherein the Ti is in a tetrahedral geometry and exclusively substituted for Si in the silica framework. Such titanosilicates find use as catalysts for epoxidation, hydroxylation, C—H bond oxidation, oxidation of sulfides, aminolysis of epoxide and amoximation, with approx. 100% selectivity towards the products.
    Type: Application
    Filed: July 20, 2011
    Publication date: May 9, 2013
    Applicant: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH
    Inventors: Srinivas Darbha, Anuj Kumar
  • Patent number: 8372888
    Abstract: Provided are novel compositions which uniquely inhibit sphingosine kinase Type 1 (SphK1) and which are useful in a number of applications including killing or damaging cancer cells, inducing apoptosis, inhibiting growth, metastasis and development of chemoresistance in cancer cells, leukemia, increasing the effectiveness of anti-cancer agents, attenuating immune reactivity, inhibiting survival signaling in cancer cells, and reducing symptoms of multiple sclerosis.
    Type: Grant
    Filed: April 29, 2009
    Date of Patent: February 12, 2013
    Assignee: Enzo Therapeutics, Inc.
    Inventors: Robert E. Zipkin, Sarah Spiegel, Jeffrey Kroll Adams
  • Publication number: 20130022654
    Abstract: A once daily controlled release pharmaceutical compositions comprising tapentadol, wherein preferably the mean Tmax of tapentadol is reached after 10 hours of administration of the composition. The composition comprises tapentadol, such that it maintains serum concentration of tapentadol of at least about 20 ng/ml for at least about 17 hours after oral administration of the composition. According to one embodiment the controlled release pharmaceutical composition comprises tapentadol, which is gastroretentive.
    Type: Application
    Filed: February 7, 2011
    Publication date: January 24, 2013
    Applicant: LUPIN LIMITED
    Inventors: Ashish Ashokrao Deshmukh, Pravin Meghrajji Bhutada, Sajeev Chandran, Shirishkumar Kulkarni
  • Publication number: 20130018077
    Abstract: Provided are alkynyl phenyl derivative compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 17, 2013
    Applicant: Acucela Inc.
    Inventors: Ian Leslie Scott, Vladmir Aleksandrovich Kuksa, Mark W. Orme, Thomas Little, Anna Gall, Jennifer Gage, Feng Hong
  • Patent number: 8334322
    Abstract: Drug substances comprising a pharmaceutically acceptable organic acid addition salt of amine containing pharmaceutically active compounds useful for the treatment of a therapeutic ailment administration and exhibiting prophylactic properties when employed in non-therapeutic administration.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: December 18, 2012
    Assignee: Pisgah Laboratories, LLC
    Inventors: David William Bristol, Clifford Riley King, Joseph Pike Mitchener, Jr., Vicki Haynes Audia
  • Patent number: 8314151
    Abstract: Provided are novel compositions and analogs which are useful in a number of applications, indications and diseases, as well as for monitoring pharmakinetics and patient management. These compounds and analogs are applicable to treating tumors of the central nervous system, e.g., glioblastoma (GBM).
    Type: Grant
    Filed: August 31, 2009
    Date of Patent: November 20, 2012
    Assignee: Enzo Therapeutics, Inc.
    Inventors: Sarah Spiegel, Robert Elliot Zipkin, Jeffrey Kroll Adams
  • Patent number: 8309768
    Abstract: A number of FTY720-derived compounds with antitumor activity are described. These compounds include the compounds of formula I: wherein R1 is independently selected from the group consisting of hydrogen, methyl. methoxy, and hydroxyl; R2 is independently selected from the group consisting of hydrogen, methoxy, and hydroxyl; R3 is independently selected from the group consisting of alkyl and cyclo-alkyl; and n is independently selected from 0 to 6. The compounds have lower immunosuppressive side effects as a result of not being phosphorylated by sphingosine kinase 2.
    Type: Grant
    Filed: November 29, 2011
    Date of Patent: November 13, 2012
    Assignee: The Ohio State University Research Foundation
    Inventors: Ching-Shih Chen, Samuel K. Kulp, Dasheng Wang, John C. Byrd, Natarajan Muthusamy
  • Publication number: 20120237448
    Abstract: Provided are novel compositions and analogs which are useful in a number of applications, indications and diseases, as well as for monitoring pharmakinetics and patient management. These compounds and analogs are applicable to treating tumors of the central nervous system, e.g., glioblastoma (GBM).
    Type: Application
    Filed: August 31, 2009
    Publication date: September 20, 2012
    Inventors: Sarah Spiegel, Robert Elliot Zipkin, Jeffrey Kroll Adams
  • Patent number: 8268894
    Abstract: Methods and compositions for treating disease caused by infectious agents, particularly tuberculosis. In particular, methods and compositions comprising substituted ethylene diamines for the treatment of infectious diseases are provided. In one embodiment, these methods and compositions are used for the treatment of mycobacterial infections, including, but not limited to, tuberculosis.
    Type: Grant
    Filed: November 11, 2010
    Date of Patent: September 18, 2012
    Assignees: The United States of America as Represented by the Secretary, Department of Health and Human Services, Sequella, Inc.
    Inventors: Marina Nikolaevna Protopopova, Elena Bogatcheva, Leo Einck, Richard Edward Lee, Richard Allan Slayden, Clifton E. Barry, III
  • Patent number: 8262750
    Abstract: Polyolefinic amines may be produced in a reaction comprising contacting an olefin or a polyolefin with an azo compound under free radical conditions to form a polyolefinic nitrile having an average molecular weight of at least 250, followed by reducing the polyolefinic nitrile to a corresponding polyolefinic amine. The polyolefinic amines produced by the reaction may be included as a detergent in compositions, such as fuel compositions, additive compositions, and/or carrier compositions.
    Type: Grant
    Filed: July 1, 2009
    Date of Patent: September 11, 2012
    Assignee: Afton Chemical Corporation
    Inventor: William Jay Colucci
  • Patent number: 8263809
    Abstract: The present invention relates to an improved process for the preparation of 3-[(1R,2R)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol monohydrochloride.
    Type: Grant
    Filed: July 23, 2007
    Date of Patent: September 11, 2012
    Assignee: Gruenenthal GmbH
    Inventor: Wolfgang Hell
  • Publication number: 20120220665
    Abstract: This document relates to compounds as well as methods and materials involved in modulating neurotransmitter reuptake. For example, compounds, methods for synthesizing compounds, and methods for inhibiting neurotransmitter reuptake are provided.
    Type: Application
    Filed: November 2, 2010
    Publication date: August 30, 2012
    Applicant: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Elliott Richelson, Abdul H. Fauq, Dola Sinha
  • Publication number: 20120214852
    Abstract: The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are alkoxyl derivative compounds and pharmaceutical compositions comprising these compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.
    Type: Application
    Filed: November 8, 2011
    Publication date: August 23, 2012
    Applicant: Acucela Inc.
    Inventors: Ian L. Scott, Vladimir A. Kuksa, Mark W. Orme, Thomas Little, Anna Gall, Feng Hong
  • Patent number: 8236991
    Abstract: The present invention relates to the purification of (2S,3S,5S)-5-amino-2-N,N-dibenzylamino-3-hydroxy-1,6-diphenylhexane (III) by making its crystalline acid addition salt, which can be used as such to produce Lopinavir/Ritonavir with high purity and yield.
    Type: Grant
    Filed: June 5, 2008
    Date of Patent: August 7, 2012
    Assignee: Aurobindo Pharma Ltd.
    Inventors: V Raghava Reddy Ambati, Srinivas Garaga, Ramesh Dandala, Sivakumaran Meenakshisunderam
  • Publication number: 20120196819
    Abstract: Compositions and methods for the treatment and control of various conditions in an animal which comprises administering to said animal an effective amount of a immediate release composition of about 0.5% to 50% wt/wt of active ingredient together with excipients to a total of about 100%, wherein said compositon dissolves in a relatively short period of time, e.g., 75 seconds or less, 5 seconds or less, or 3 seconds or less, upon administration to said animal.
    Type: Application
    Filed: January 4, 2012
    Publication date: August 2, 2012
    Applicant: NEWMARKET PHARMACEUTICALS LLC
    Inventors: David ROCK, Mark RIDALL
  • Publication number: 20120172392
    Abstract: Compositions and methods are disclosed for inhibiting semicarbazide-sensitive amine oxidase (SSAO), also known as vascular adhesion protein-1 (VAP-1). The compounds disclosed are amine-containing and amide-containing compounds. The compounds and compositions are useful for treatment of diseases, including inflammation, inflammatory diseases and autoimmune disorders.
    Type: Application
    Filed: March 7, 2012
    Publication date: July 5, 2012
    Inventors: LUISA M. SALTER-CID, ERIC Y. WANG, MARY T. MACDONALD, JINGJING ZHAO
  • Publication number: 20120157544
    Abstract: The present invention relates to a compound of formula A, wherein R is alkyl. Compound A may be used as an intermediate in the preparation of O-desmethyl venlafaxine or a salt thereof, and the present invention provides such a preparation, as well as a process for preparing the compound of formula A.
    Type: Application
    Filed: July 14, 2010
    Publication date: June 21, 2012
    Applicant: CIPLA LIMITED
    Inventors: Rajendra Narayanrao Kankan, Dharmaraj Ramachandra Rao, Manohar Raghunath Surve
  • Patent number: 8202910
    Abstract: Methods and compositions for treating disease caused by infectious agents, particularly tuberculosis. In particular, methods and compositions comprising substituted ethylene diamines for the treatment of infectious diseases are provided. In one embodiment, these methods and compositions are used for the treatment of mycobacterial infections, including, but not limited to, tuberculosis. In certain embodiments, the present invention comprises compositions comprising novel substituted ethylene diamine compounds further comprising antitubercular agents such as rifampicin, isoniazid, pyrazinamide and ethambutol.
    Type: Grant
    Filed: October 22, 2008
    Date of Patent: June 19, 2012
    Assignee: Sequella, Inc.
    Inventors: Marina Nikolaena Protopopova, Leo Einck, Boris Nikonenko, Ping Chen
  • Publication number: 20120129894
    Abstract: The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are alkoxyl derivative compounds and pharmaceutical compositions comprising these compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.
    Type: Application
    Filed: May 19, 2011
    Publication date: May 24, 2012
    Applicant: Acucela Inc.
    Inventors: Ian L. Scott, Vladimir A. Kuksa, Mark W. Orme, Thomas Little, Anna Gall, Feng Hong
  • Publication number: 20120108848
    Abstract: Resolution of the title compound to its active isomer (R)-1-(3-hydroxyphenyl)-2-methylamino ethanol with (R)-naproxen as a resolving agent.
    Type: Application
    Filed: December 22, 2010
    Publication date: May 3, 2012
    Applicant: Divi's Laboratories Limited
    Inventors: Murali Krishna Prasad Divi, Padakandla Gundu Rao, Bolneni Nageswara Rao, Medepudi Ramesh Babu, Mutyala Krishnaji Rao, Allupati Padmanav Patro
  • Patent number: 8158827
    Abstract: Disclosed are cationic lipid compounds and compositions of lipid aggregates for delivery of macromolecules and other compounds into cells. The compounds can be used alone or in combination with other compounds to prepare liposomes and other lipid aggregates suitable for transfection or delivery of compounds to target cells, either in vitro or in vivo. The compounds are preferably polycationic and preferably form highly stable complexes with various anionic macromolecules, particularly polyanions such as nucleic acids. These compounds have the property, when dispersed in water, of forming lipid aggregates which associate strongly, via their cationic portion, with polyanions. Also disclosed are intermediates for preparing the compound and compositions of the invention and methods of using the compounds to introduce other compounds into cells.
    Type: Grant
    Filed: January 14, 2009
    Date of Patent: April 17, 2012
    Assignee: Life Technologies Corporation
    Inventors: Yongliang Chu, Malek Masoud, Gulilat Gebeyehu
  • Publication number: 20120078016
    Abstract: Disclosed is a method of making a 2-substituted-1,4-benzenediamine by nucleophilic aromatic substitution.
    Type: Application
    Filed: January 28, 2011
    Publication date: March 29, 2012
    Inventors: John Michael GARDLIK, Garry Steven Garrett, Bryan Patrick Murphy, Guiru Zhang, Robert Edward Shumate, James S. Anderson